The peer-reviewed publication in Cancer Cell provides external validation of firmonertinib's activity in PACC-mutant NSCLC, a large underserved population. The ongoing Phase 3 ALPACCA trial is the next binary catalyst; monitor enrollment updates and any interim data readouts.
Price Chart
Executive Summary
ArriVent BioPharma announced the publication of Phase 1b (FURMO-002) results for firmonertinib in EGFR PACC-mutant NSCLC in Cancer Cell. The data showed a 68% confirmed ORR and 16.0-month median PFS at the 240 mg dose, with meaningful intracranial activity. The publication supports the ongoing global Phase 3 ALPACCA trial, but no new financial data or regulatory milestones were disclosed.
Key Facts
- Phase 1b FURMO-002 results published in Cancer Cell for firmonertinib in EGFR PACC-mutant NSCLC
- 68% confirmed ORR and 16.0-month median PFS (BICR) at 240 mg dose in front-line setting
- 47% confirmed intracranial ORR (8/17), including 41% complete responses among patients with baseline brain metastases
- 80% of evaluable patients achieved complete molecular response by cycle 3, with 70% ORR vs 20% without clearance
- EGFR PACC mutations represent ~12% of EGFR-mutant tumors with no established targeted standard of care
- Global Phase 3 ALPACCA trial (NCT07185997) is actively enrolling
- Firmonertinib already has FDA Breakthrough Therapy Designation for EGFR exon 20 insertion mutations and Orphan Drug Designation for EGFR/HER2/HER4 mutations
Financial Impact
No financial figures disclosed; clinical-stage company with no reported revenue from firmonertinib in this filing
Risk Factors
- Phase 3 ALPACCA trial may fail to replicate Phase 1b results
- Competition from osimertinib and other emerging EGFR TKIs in PACC-mutant space
- No regulatory submission timeline provided for PACC-mutant indication in the US
- Clinical-stage company with no approved products in the US; reliance on single lead asset
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-116736 |
| Document: tm2627799d1_ex99-1.htm | 0001104659-26-116736 |
| Document: 0001104659-26-116736-index-headers.html | 0001104659-26-116736 |
| Document: 0001104659-26-116736-index.html | 0001104659-26-116736 |
| Document: 0001104659-26-116736.txt | 0001104659-26-116736 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $15.22 (−35.62%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $15.22 (−27.52%) |
Oct 23, 2026 2d ago | Press Release | $21.00 | awaiting T+5 | — | $15.22 (−27.52%) |
Oct 19, 2026 7d ago | 8-K | $17.94 | awaiting T+5 | — | $15.22 (−15.16%) |
Oct 13, 2026 12d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $15.22 (−6.05%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $15.22 (−5.41%) |
Oct 8, 2026 17d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $15.22 (+9.03%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $15.22 (−0.86%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $15.22 (+49.27%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $15.22 (−50.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers